Insider Selling: Neuronetics, Inc. (NASDAQ:STIM) CEO Sells 40,992 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 40,992 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $134,453.76. Following the completion of the sale, the chief executive officer now owns 1,283,362 shares in the company, valued at approximately $4,209,427.36. The trade was a 3.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Neuronetics Stock Down 1.8 %

Shares of STIM stock opened at $3.90 on Friday. The stock has a market cap of $118.37 million, a P/E ratio of -3.17 and a beta of 2.17. Neuronetics, Inc. has a 52 week low of $0.52 and a 52 week high of $5.07. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The company’s fifty day simple moving average is $2.14 and its two-hundred day simple moving average is $1.40.

Institutional Trading of Neuronetics

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in Neuronetics by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock worth $506,000 after purchasing an additional 8,466 shares in the last quarter. David J Yvars Group raised its position in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after buying an additional 14,825 shares in the last quarter. Tradewinds LLC. purchased a new stake in shares of Neuronetics during the 4th quarter valued at about $32,000. XTX Topco Ltd purchased a new stake in shares of Neuronetics during the 4th quarter valued at about $49,000. Finally, GSA Capital Partners LLP raised its position in shares of Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after buying an additional 30,837 shares in the last quarter. Hedge funds and other institutional investors own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.